These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20828056)

  • 1. [Germany's Novartis Chief proposes "More competition through decentralized contracts"].
    Kosche D; Färber L
    MMW Fortschr Med; 2010 Aug; 152(31-33):6-7. PubMed ID: 20828056
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness data on biologics needed.
    Sheridan C; Katsnelson A
    Nat Biotechnol; 2005 Mar; 23(3):272-3. PubMed ID: 15765069
    [No Abstract]   [Full Text] [Related]  

  • 3. The quiet revolution.
    Nat Biotechnol; 2003 Jul; 21(7):715. PubMed ID: 12833072
    [No Abstract]   [Full Text] [Related]  

  • 4. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
    Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH
    Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How Genentech Novartis stifled a promising drug: biotech firm tried to pursue a peanut allergy inject, but contract got in way; Zach avoids a "kiss of death".
    Hamilton DP
    Wall St J (East Ed); 2005 Apr; ():A1, A10. PubMed ID: 15926244
    [No Abstract]   [Full Text] [Related]  

  • 6. Redesigner drugs.
    Dove A
    Nat Biotechnol; 2004 Aug; 22(8):953-7. PubMed ID: 15286643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical industry research and cost savings in community-acquired pneumonia.
    Kessler LA; Waterer GW; Barca R; Wunderink RG
    Am J Manag Care; 2002 Sep; 8(9):798-800. PubMed ID: 12234020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precompetitive research: a new prescription for drug development?
    Woodcock J
    Clin Pharmacol Ther; 2010 May; 87(5):521-3. PubMed ID: 20407454
    [No Abstract]   [Full Text] [Related]  

  • 9. [Drug manufacturer on the savings package of Ulla Schmidt. "Grip in the moth box of planned economics"].
    Schmidt K
    MMW Fortschr Med; 2001 Nov; 143(44):52. PubMed ID: 11732398
    [No Abstract]   [Full Text] [Related]  

  • 10. Should the patent system for new medicines be abolished?
    DiMasi JA; Grabowski HG
    Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmaceutical advertising versus research spending: are profits more important than patients?
    Mukherjee D; Topol EJ
    Am Heart J; 2003 Oct; 146(4):563-4. PubMed ID: 14564305
    [No Abstract]   [Full Text] [Related]  

  • 12. Uneasy alliance--clinical investigators and the pharmaceutical industry.
    Bodenheimer T
    N Engl J Med; 2000 May; 342(20):1539-44. PubMed ID: 10816196
    [No Abstract]   [Full Text] [Related]  

  • 13. Are drug too expensive in Canada? No.
    Williams R; Marion J
    Can Fam Physician; 2006 May; 52():573-6, 578-81. PubMed ID: 16739822
    [No Abstract]   [Full Text] [Related]  

  • 14. The people vs patents.
    New Sci; 2002 Jul; 175(2351):3. PubMed ID: 12625337
    [No Abstract]   [Full Text] [Related]  

  • 15. Big Pharma's Commedia.
    Steele FR
    Cell; 2005 Dec; 123(6):971-3. PubMed ID: 16360023
    [No Abstract]   [Full Text] [Related]  

  • 16. Medicine and the pharmaceutical industry.
    Baxter P
    Dev Med Child Neurol; 2006 Aug; 48(8):627. PubMed ID: 16836771
    [No Abstract]   [Full Text] [Related]  

  • 17. The definition and role of quality of life in Germany's early assessment of drug benefit: a qualitative approach.
    Lohrberg D; Augustin M; Blome C
    Qual Life Res; 2016 Feb; 25(2):447-455. PubMed ID: 26242250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Productivity counts--but the definition is key.
    Mervis J
    Science; 2005 Jul; 309(5735):726. PubMed ID: 16051784
    [No Abstract]   [Full Text] [Related]  

  • 19. [Effects of pharmacy market deregulation regarding patient-centred drug care in Germany from a health economics perspecitve].
    Rumm R; Böcking W
    Dtsch Med Wochenschr; 2013 Mar; 138(9):441-4. PubMed ID: 23423941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical drug trials in Germany--an assessment of current status from the viewpoint of industry].
    Baumbauer E
    Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():646-50. PubMed ID: 9101960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.